Total
0
Shares
Biotron (ASX:BIT) - Managing Director & CEO, Dr Michelle Miller
Managing Director & CEO, Dr Michelle Miller
Source: Biotron
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotron’s (BIT) lead drug, BIT225, has been effective against COVID-19 in animals
  • The drug was given orally and significantly reduced viral load in the lungs and blood
  • Additionally, the company also tested BIT225 in an in-vitro study in cell cultures to assess the ability of the drug on the highly infectious delta strain, which was successful
  • Biotron is now in discussions with its USA advisors and consultants to progress the drug into human trials for COVID-19
  • On the market today, Biotron is up 68.6 per cent and trading at 8.6 cents per share

Biotron’s (BIT) lead drug, BIT225, has been effective against COVID-19 in animals.

The drug was given orally and significantly reduced viral load in the lungs and blood of animals with SARS-CoV-2. Notably, there was also a reduction of the virus in the blood.

Increased levels of pro-inflammatory cytokines, known as a cytokine storm, are linked to severe illness and death in people infected with the virus. Controlling this increase is essential for the successful treatment of COVID-19.

BIT225 reduced these cytokine storms in the lungs and blood.

During the course of infection by COVID-19, the animals generally develop severe disease that is reflected in the loss of body weight. The animals treated with BIT225 did not lose weight throughout the study.

Additionally, the company also tested BIT225 in an in-vitro study in cell cultures to assess the ability of the drug on the highly infectious delta strain. Data from this study showed that BIT225 reduced the delta virus in the cell structures by more than 99.99 per cent.

Bitron is now in discussions with its USA advisors and consultants to progress the drug into human trials for COVID-19.

“These results suggest that BIT225 may have benefit over other known antiviral agents. We will actively pursue all avenues to progress this Biotron drug into human trials as quickly as possible,” Managing Director Michelle Miller said.

On the market today, Biotron was up 68.6 per cent and is trading at 8.6 cents per share at 10:59 pm AEDT.

BIT by the numbers
More From The Market Herald
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) advances Meta-Twin for digital health assessments

Advanced Human Imaging (AHI) has announced the advancement of its Meta-Twin offering, a real-time, on-screen digital health assessment.
The Market Herald Video

" Security Matters (ASX:SMX): Addressing fashion’s $40-billion problem

Australian company Security Matters is taking the lead in helping the fashion industry’s attempts to address a $40-billion problem.
Adriatic Metals PLC (ASX:ADT) - CEO, Paul Cronin

" Adriatic Metals (ASX:ADT) releases silver assays for Rupice Mineral Resource

Adriatic Metals (ADT) has released silver assays for its wholly-owned Vares Silver Project in Bosnia and Herzegovina.
Turaco Gold (ASX:TCG) -Managing Director, Justin Tremain

" Turaco Gold (ASX:TCG) receives results from Bouake North

Turaco Gold (TCG) has received results from its recently completed auger drilling program at the Bouake North prospect in Côte d’Ivoire.